SLE a Distancia
Grupos MINDACT
MINDACT Population
DMFS at 5 Years
cL
/
MP Low
no ACT
97.6% (96.9 – 98.1)
cH
/
MP Low
no ACT
94.7%
(92.5 – 96.2)
cL
/
MP High
no ACT
93.9% (89.6 – 96.5)
cH
/
MP High
ACT
90.6% (89.0 – 92.0)
Only a
genome-driven assay
developed test like MammaPrint can be
combined with clinicopathological factors to identify 4 distinct subgroups
of patients with different metastatic risk potential
Primary
Analysis
